BR112012015967B1 - uso de compostos de fórmula geral (i) e composição farmacêutica - Google Patents
uso de compostos de fórmula geral (i) e composição farmacêutica Download PDFInfo
- Publication number
- BR112012015967B1 BR112012015967B1 BR112012015967A BR112012015967A BR112012015967B1 BR 112012015967 B1 BR112012015967 B1 BR 112012015967B1 BR 112012015967 A BR112012015967 A BR 112012015967A BR 112012015967 A BR112012015967 A BR 112012015967A BR 112012015967 B1 BR112012015967 B1 BR 112012015967B1
- Authority
- BR
- Brazil
- Prior art keywords
- carboline
- cech
- cec
- methyl
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102009060811 | 2009-12-28 | ||
| US28239510P | 2010-02-02 | 2010-02-02 | |
| PCT/DE2010/001530 WO2011079841A1 (de) | 2009-12-28 | 2010-12-28 | Beta-carboline zur behandlung von hörschäden und schwindel |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112012015967A2 BR112012015967A2 (pt) | 2016-04-19 |
| BR112012015967B1 true BR112012015967B1 (pt) | 2019-08-27 |
Family
ID=44246908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012015967A BR112012015967B1 (pt) | 2009-12-28 | 2010-12-28 | uso de compostos de fórmula geral (i) e composição farmacêutica |
Country Status (17)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015023261A2 (pt) | 2013-03-14 | 2017-07-18 | Massachusetts Inst Technology | composições e métodos para expansão e cultura de células-tronco epiteliais |
| SI2968284T1 (sl) | 2013-03-14 | 2021-08-31 | Osteoqc Inc. | Alkil-amin harmin derivati za pospeševanje rasti kosti |
| EP2853533A1 (de) * | 2013-09-29 | 2015-04-01 | Audiocure Pharma GmbH | 6-Fluor-9-methyl-ß-carbolin |
| CN107073042A (zh) | 2014-09-03 | 2017-08-18 | 布里格海姆妇女医院公司 | 用于产生内耳毛细胞来治疗听力损失的组合物、系统和方法 |
| CA3010610A1 (en) | 2016-01-08 | 2017-07-13 | The Brigham And Women's Hospital, Inc. | Production of differentiated enteroendocrine cells and insulin producing cells |
| US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
| US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
| US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
| EP3321264A1 (en) * | 2016-11-14 | 2018-05-16 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Selective inhibitors of genotoxic stress-induced ikk/nf-kb pathways |
| AU2017386417B2 (en) | 2016-12-30 | 2022-07-14 | Frequency Therapeutics, Inc. | 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells |
| JP7695496B2 (ja) | 2018-08-14 | 2025-06-19 | オシフィ セラピューティクス リミティド ライアビリティ カンパニー | フルオロβ－カルボリン化合物 |
| EP3836923B1 (en) | 2018-08-14 | 2024-10-16 | OssiFi Therapeutics LLC | Pyrrolo - dipyridine compounds for the treatment of bone loss |
| WO2020037326A1 (en) | 2018-08-17 | 2020-02-20 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating foxo |
| WO2020037323A1 (en) | 2018-08-17 | 2020-02-20 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by upregulating jag-1 |
| EP3849530A4 (en) | 2018-09-12 | 2022-06-22 | Hough Ear Institute | METHODS OF TREATMENT OF HEARING LOSS AFTER COCHLEAR IMPLANT SURGERY |
| EP3772515A1 (en) * | 2019-08-09 | 2021-02-10 | Audiocure Pharma GmbH | Stable polymorphic form of 6-fluoro-9-methyl-9h-ss-carboline and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3240514A1 (de) | 1982-10-29 | 1984-05-03 | Schering AG, 1000 Berlin und 4709 Bergkamen | Ss-carboline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
| CA2140722A1 (en) | 1994-01-24 | 1995-07-25 | Joseph A. Jakubowski | Beta-carboline thromboxane synthase inhibitors |
| US20040038970A1 (en) * | 1998-06-12 | 2004-02-26 | Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp. | Beta-carboline compounds |
| EP1086101B1 (en) * | 1998-06-12 | 2002-12-18 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Beta-carboline compounds |
| US20050137220A1 (en) * | 2003-07-23 | 2005-06-23 | Pharmacia Corporation | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors |
| DE102007009264A1 (de) * | 2007-02-26 | 2008-08-28 | Ellneuroxx Ltd. | 9-Alkyl-ß-Carboline zur Behandlung von neurodegenerativen Erkrankungen |
-
2010
- 2010-12-28 CA CA2785233A patent/CA2785233C/en active Active
- 2010-12-28 CN CN2010800630256A patent/CN102844029A/zh active Pending
- 2010-12-28 AU AU2010338669A patent/AU2010338669A1/en not_active Abandoned
- 2010-12-28 MX MX2012007678A patent/MX2012007678A/es not_active Application Discontinuation
- 2010-12-28 KR KR1020127017073A patent/KR20120098855A/ko not_active Withdrawn
- 2010-12-28 JP JP2012546361A patent/JP5627705B2/ja active Active
- 2010-12-28 BR BR112012015967A patent/BR112012015967B1/pt active IP Right Grant
- 2010-12-28 EP EP10812791.1A patent/EP2519238B1/de active Active
- 2010-12-28 DE DE112010005017T patent/DE112010005017A5/de not_active Withdrawn
- 2010-12-28 WO PCT/DE2010/001530 patent/WO2011079841A1/de not_active Ceased
- 2010-12-28 RU RU2012132429/04A patent/RU2012132429A/ru not_active Application Discontinuation
- 2010-12-28 SG SG2012042438A patent/SG181599A1/en unknown
- 2010-12-28 NZ NZ600478A patent/NZ600478A/xx unknown
- 2010-12-28 US US13/514,171 patent/US9107914B2/en active Active
-
2012
- 2012-06-07 IN IN5066DEN2012 patent/IN2012DN05066A/en unknown
- 2012-06-18 ZA ZA2012/04476A patent/ZA201204476B/en unknown
- 2012-06-26 IL IL220661A patent/IL220661A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120098855A (ko) | 2012-09-05 |
| JP5627705B2 (ja) | 2014-11-19 |
| IL220661A (en) | 2016-03-31 |
| WO2011079841A1 (de) | 2011-07-07 |
| IN2012DN05066A (cg-RX-API-DMAC7.html) | 2015-10-09 |
| IL220661A0 (en) | 2012-08-30 |
| RU2012132429A (ru) | 2014-02-10 |
| JP2013515752A (ja) | 2013-05-09 |
| EP2519238A1 (de) | 2012-11-07 |
| DE112010005017A5 (de) | 2012-10-04 |
| BR112012015967A2 (pt) | 2016-04-19 |
| CN102844029A (zh) | 2012-12-26 |
| SG181599A1 (en) | 2012-07-30 |
| US9107914B2 (en) | 2015-08-18 |
| MX2012007678A (es) | 2012-09-12 |
| NZ600478A (en) | 2013-10-25 |
| CA2785233C (en) | 2018-10-09 |
| US20130028958A1 (en) | 2013-01-31 |
| ZA201204476B (en) | 2014-01-29 |
| AU2010338669A1 (en) | 2012-06-21 |
| CA2785233A1 (en) | 2011-06-07 |
| EP2519238B1 (de) | 2014-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5627705B2 (ja) | 聴力損傷および目まいの治療用のβ−カルボリン | |
| ES2248950T3 (es) | Utilizacion de cuatro derivados de k-252a. | |
| ES2989745T3 (es) | Terapia de intervalos para el tratamiento de enfermedades oculares | |
| WO2010133742A1 (es) | Uso de derivados de quinazolinas en enfermedades neurodegenerativas | |
| JP2026500459A (ja) | Ｎ－ｎ－ジメチルトリプタミン（ｄｍｔ）およびｄｍｔ類似体組成物、その作製方法、ならびに使用方法 | |
| US20240245693A1 (en) | Compositions and methods of tissue regeneration therapy | |
| DK2941429T3 (en) | Fluoro-9-methyl-beta-carboline | |
| ES2447834T3 (es) | Composición y método para tratar o prevenir la fibrosis del músculo esquelético | |
| CN105362273A (zh) | 7-烷氧基防己诺林碱类化合物在制备治疗和改善抑郁症状的药物中的用途 | |
| JP2000309545A (ja) | 愛玩動物の年齢関連行動障害治療方法および治療用組成物 | |
| Yamamoto et al. | Effects of locus coeruleus stimulation on muricide in olfactory bulbectomized and raphe lesioned rats | |
| WO2021214950A1 (ja) | 精神疾患を治療、予防又は管理するための医薬組成物 | |
| ES2827011T3 (es) | Terapia de intervalos para el tratamiento de la pérdida de visión en seres humanos con glaucoma | |
| US20110319463A1 (en) | Preventive or therapeutic agents for optic nerve disorders comprising 4,6-dichloro-1h-indole-2-carboxylic acid derivatives or salts thereof as active ingredients | |
| JP2009235069A (ja) | ３’，５−ジ−２−プロペニル−（１，１’−ビフェニル）−２，４’−ジオールを有効成分として含有する視神経障害の予防又は治療剤 | |
| HK1164884A (en) | Prophylactic or therapeutic agent for optic nerve disorders comprising 4,6-dichloro-1h-indole-2-carboxylic acid derivative or salt thereof as active ingredient | |
| HK40039902A (en) | Compounds for treatment of cardiac arrhythmias and heart failure | |
| JP2008100948A (ja) | 硫化水素および／または硫化水素塩を含有する神経細胞分化促進剤およびその方法 | |
| HK1222844B (en) | FLUOR-9-METHY-β-CARBOLINES | |
| JP2010526830A (ja) | 黒色腫の処置のためのｈｄａｃ阻害剤の使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/12/2010, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/12/2010, OBSERVADAS AS CONDICOES LEGAIS |